Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress

Recruiting now · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Prematurity, Respiratory Disease, Ventilator Lung; Newborn

In brief

Use of caffeine citrate in late-preterm infants with respiratory distress is questionable. Oliphant and colleagues found in a recently published study that caffeine therapy use in late-preterm infants at a loading dose of 20 and 40 mg/kg and maintenance dose of 10 and 20 mg/kg/day reduces the incidence of intermittent hypoxia events by 61 and 67% respectively. The investigators hypothesized that caffeine will improve respiratory drive, prevent apnea, shorten the hospital stay and improve arousal state in late preterm infants. The investigators aim to study the effect of caffeine citrate on late preterm babies as regard duration of respiratory support, duration of hospital stay, respiratory morbidity, incidence and frequency of apnea.

Key facts

Study ID
NCT06026163
Run by
Ministry of Health, Saudi Arabia
People needed
134
Starts
2023-10-12
Expected to finish
2028-01-01
Last updated by the study team
2025-06-27

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.